Artis BioSolutions announced the launch of its Genetics Medicines Center of Excellence in Bilbao, Spain, where it already has a facility specializing in synthetic DNA manufacturing. The company, which also has facilities in Boston and San Diego, supports genetic medicine developers with manufacturing processes. It was cofounded by Harvard University, MIT and Boston research hospitals as Landmark Bio.…
Codis completes acquisition of Catalent manufacturing plant
Codis announced today that it completed its previously announced acquisition of a UK-based manufacturing facility from Catalent. The Haverhill, England-based company agreed to acquire the oral solid dose (OSD) development and manufacturing plant in Nottingham last month. The facility adds OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single…
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing
Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience’s advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience’s production in that region…
Fujifilm Biotechnologies selected for FDA PreCheck Pilot Program
A Fujifilm Biotechnologies’ commercial-scale cell culture manufacturing facility has been selected for the FDA’s PreCheck Pilot Program, the company announced. The CDMO’s Holly Springs, North Carolina, facility was selected as one of seven participants in the program designed to strengthen United States pharmaceutical manufacturing capabilities and accelerate patient access to critical medicines. “We are honored…
Otsuka ICU Medical to invest $500M in IV solutions manufacturing in the US
Otsuka ICU Medical today announced plans to invest more than $500 million to expand its U.S. IV solutions manufacturing in Texas. The companies (Otsuka Pharmaceutical Factory and ICU Medical), which launched this joint venture last year, plan to deliver a new facility and significant upgrades to its existing operations in Austin, Texas. They expect the…
Evonik to invest $100M in US drug contract manufacturing site
Evonik announced today that it plans to invest $100 million to expand its pharmaceutical manufacturing capabilities in the U.S. The Essen, Germany-based company is investing in its Tippecanoe Labs site in Lafayette, Indiana, which houses one of the world’s largest facilities for the production of active pharmaceutical ingredients (APIs). Over the next five years, the…
Codis acquires oral solid dose plant from Catalent
Codis announced today that it agreed to acquire an oral solid dose (OSD) development and manufacturing plant from Catalent. Acquiring the Nottingham, UK-based facility will add OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single partner path for integrated spray dry solutions. It can now provide development through clinical…
Besins Healthcare acquires pharmaceutical manufacturing company UniD
Besins Healthcare announced today that it acquired UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company. UniD specializes in long-acting drug-delivery technologies, bringing decades of expertise to Besins, which delivers a range of hormone therapies. The company works with advanced polymer technology for complex long-acting delivery systems, including implants and vaginal rings. The companies expect…
Shoko to begin manufacturing pharmaceutical product in Korea
Shoko announced today that it completed work on a manufacturing plant for its new pharmaceutical excipient, Viscomedi. The facility saw its full-scale commercial production commence in February 2026. Excipients are the inactive, non-drug substances formulated alongside an active pharmaceutical ingredient (API). South Korea-based Hannong Chemicals has been developing a partially neutralized polyacrylate product for pharmaceutical…
Report: Octapharma to make $1.5B expansion in South Carolina
Octapharma is investing $1.5 billion to build a new massive complex, including manufacturing capabilities, in South Carolina, according to the Charlotte Business Journal. The Swiss company, which develops and manufactures medicines for hematology, immunotherapy and critical care, is behind an effort labeled “Project Palmetto Rock,” the report says. It states that York County Council held a meeting…